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BACKGROUND: A dichotomous index combining two gene expression assays, HOXB13:IL17BR (H:I) and molecular grade index
(MGI), was developed to assess risk of recurrence in breast cancer patients. The study objective was to demonstrate the prognostic
utility of the combined index in early-stage breast cancer.
METHODS: In a blinded retrospective analysis of 588 ER-positive tamoxifen-treated and untreated breast cancer patients from the
randomised prospective Stockholm trial, H:I and MGI were measured using real-time RT–PCR. Association with patient outcome
was evaluated by Kaplan–Meier analysis and Cox proportional hazard regression. A continuous risk index was developed using
Cox modelling.
RESULTS: The dichotomous H:IþMGI was significantly associated with distant recurrence and breast cancer death. The 450% of
tamoxifen-treated patients categorised as low-risk had o3% 10-year distant recurrence risk. A continuous risk model (Breast Cancer
Index (BCI)) was developed with the tamoxifen-treated group and the prognostic performance tested in the untreated group was
53% of patients categorised as low risk with an 8.3% 10-year distant recurrence risk.
CONCLUSION: Retrospective analysis of this randomised, prospective trial cohort validated the prognostic utility of H:IþMGI and was
used to develop and test a continuous risk model that enables prediction of distant recurrence risk at the patient level.
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Conventional criteria used for risk prediction of breast cancer
patients include clinicopathological characteristics such as lymph
node involvement, tumour size, histological tumour grade and
hormone receptor status (Carter et al, 1989; Galea et al, 1992; Press
et al, 1997). However, even with utilisation of these prognostic and
treatment predictive factors under and overtreatment can occur
(van’t Veer and Bernards, 2008). Using traditional risk classifica-
tions, a large proportion of patients are classified as intermediate
risk, which is uninformative for choosing optimal treatment
strategies for the individual patients. Currently, the selection
criteria for using or withholding chemotherapy are coarsely
defined; however, this selection is of major importance in order
to avoid unnecessary toxic side effects associated with therapy
(Goldhirsch et al, 2009). Adjuvant treatment decisions based on
clinicopathological characteristics as recommended by guidelines,
such as the St Gallen breast cancer consensus guidelines and the
Adjuvant! Online tool (http://www.adjuvantonline.com), can be
used for assessing risks and benefits associated with adjuvant
therapy (Ravdin et al, 2001; Goldhirsch et al, 2006, 2009).
With the development of prognostic and predictive gene
expression signatures, clinicians can be provided with information
beyond the traditional criteria to guide treatment selection.
Adjunctive to other standard risk factors, such as tumour size,
tumour grade, hormone receptor status and nodal status,
integration of gene expression signatures in the clinic provides
the potential to more accurately identify low- and high-risk
patients for better informed treatment-decision making. Despite a
lack of overlapping genes in different predictive gene signatures,
the risk classification of different tumours can be equivalent
between different signatures (Desmedt and Sotiriou, 2006; Fan
et al, 2006), whereas it is evident that using conventional criteria,
as compared with these novel risk stratification tools, a significant
proportion of the patients are misclassified (van de Vijver et al,
2002; Goldstein et al, 2008).
In a previous study, it was demonstrated that the combination of
HOXB13:IL17BR (H:I) and molecular grade index (MGI), two
independent prognostic markers, outperformed either index alone
in predicting risk of recurrence in breast cancer patients (Ma et al,
2004, 2008). HOXB13:IL17BR is an independent prognostic factor
for patients with oestrogen receptor (ER) positive and node
negative disease that has also been shown to be a negative
predictive factor of tamoxifen benefit (Ma et al, 2004, 2006; Goetz
et al, 2006; Jerevall et al, 2008). HOXB13 separately can also
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sidentify patients with limited benefit of endocrine treatment. This
has been shown for gene expression, as well as protein levels
(Jerevall et al, 2008, 2010). Molecular grade index is a gene
expression assay, comprised of five genes related to histological
grade and tumour progression, which recapitulates tumour grade
and can predict clinical outcome with high performance (Ma et al,
2008). With the combinatorial approach of H:I and MGI, it was
shown that breast cancer patients could be stratified into three risk
groups with better risk prediction of distant metastasis in ER
positive, lymph node-negative patients.
In this study, we have further validated the prognostic utility of
the dichotomous H:I and MGI index retrospectively in a large
patient cohort from the prospective randomized Stockholm trial of
low risk, ER positive, node negative, tamoxifen-treated or
untreated patients (Rutqvist and Johansson, 2007). In addition,
to facilitate individualised risk assessment in the clinical setting, a
continuous predictor based on the H:I and MGI referred to as the
Breast Cancer Index (BCI) was developed and tested. Within this
cohort from the Stockholm trial, BCI is shown to predict risk of
recurrence at the individual level.
PATIENTS AND METHODS
Patients and tumour samples
The Stockholm breast cancer study group conducted a randomised
tamoxifen trial during 1976 through 1990 within a total of 2738
postmenopausal women with invasive early-stage disease (Rutqvist
and Johansson, 2007). The trial included a lymph node negative
low-risk group comprising 1780 patients with tumours p30mm in
diameter, randomised to 2 years of adjuvant tamoxifen (40mg
daily) vs control. The control patients were systemically untreated
and did not receive any chemotherapy. In 1983, a new trial was
initiated, in which recurrence-free patients, after 2 years of
tamoxifen treatment, were randomised to 3 more years of
tamoxifen or no further therapy. As a result of the new trial, the
patients in the tamoxifen arm were treated either for 2 or 5 years.
In the Stockholm cohort, the benefit from tamoxifen was largely
independent of treatment duration (Rutqvist and Johansson,
2007).
For this study, tumour blocks from 808 patients were received
(tamoxifen treated (2–5 years) and untreated). As tumour grade
was not determined during the actual trial, it was determined
retrospectively, by one pathologist blinded to outcome. The
tumours were graded according to the Nottingham system. After
pathology review, 37 cases were excluded because of insufficient
number of tumour cells in the sample, or only containing
carcinoma in situ. The remaining subset (771 tumour blocks)
was well balanced to the original low-risk cohort regarding the
tumour characteristics, such as tumour size of p20mm (78 vs
81%), positive ER status (78 vs 80%) and tamoxifen treatment
(52 vs 50%).
The standard procedure for tissue collection was fixation in 4%
phosphate-buffered formalin and embedment in paraffin. Follow-
up data were collected from regional population registers and the
Swedish Cause of Death Registry. The mean follow-up period for
patients in the present investigation was 17 years. The retro-
spective investigation of the collected tumour samples was
approved by the ethical committee at the Karolinska University
Hospital. According to the approval, informed consent from the
patients was not required.
Hormone receptor status
Status of ER, progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) was assessed retrospectively with
immunohistochemistry. ER and PR were examined using the
Ventana automated slide stainer (Ventana Medical Systems, SA,
Cedex, France). Primary monoclonal antibodies were mouse anti-
ER antibody (clone 6F11) and mouse anti-PR antibody (clone 16).
Cut-off level was set to 25% positively stained tumour cell nuclei.
In cases when immunohistochemical data for ER were missing
(12%), ER status as determined in clinical routine practice at time
of diagnosis was used (Wrange et al, 1978), with a cut-off level of
0.05fmolmg
 1 DNA. For HER2 status, tissue was stained and
scored as previously described (Jerevall et al, 2010).
Gene expression analysis by real-time RT–PCR and
calculation of gene expression indices
Molecular grade index, H:I and BCI analysis were carried out
blinded to outcome. The genes analysed were HOXB13, IL17BR
(HOXB13:IL17BR index or H:I), BUB1B, CENPA, NEK2, RAC-
GAP1, RRM2 (molecular grade index), ACTB, HMBS, SDHA
and UBC (reference genes). Primer and probe sequences for
these genes were the same as previously described (Ma et al,
2006, 2008). From each sample, 10mm tissue sections were cut.
To enrich for tumour content, all sections were subjected to
manual macrodissection before RNA extraction. RNA extraction
from formalin-fixed paraffin-embedded (FFPE) sections was
carried out as before (Ma et al, 2006). Prior to TaqMan RT–
PCR, total RNA was reverse transcribed, and the resulting cDNA
was pre-amplified by performing 10 rounds of PCR using the
PreAmp Master Mix Kit per manufacturer’s instructions (Applied
Biosystems, Carlsbad, CA, USA). The pre-amplified products
were analysed by TaqMan RT–PCR as previously described (Ma
et al, 2008). H:I and MGI were calculated as previously described
(Ma et al, 2006, 2008).
Development of a continuous risk model
Previously, we reported the categorical combination of binary H:I
(cut-off¼0.06) and MGI (cut-off¼0) into three risk groups as
follows: low risk, low MGI; intermediate risk, low H:I and high
MGI; and high risk, high H:I and high MGI. Here a continuous
risk model was built by combining H:I and MGI as continuous
variables, using the ER-positive patients in the tamoxifen arm of
the trial (n¼314). We first checked linearity of these two variables
by fitting a Cox proportional hazard regression model with
restricted cubic splines, and H:I demonstrated significant non-
linearity. We used a polynomial function of H:I to approximate
the restricted cubic spline, and the final model was selected by
comparing Cox regression models using Akaike Information
Criterion. The resulting predictor from the final Cox regression
model was then re-scaled into the range of 0–10, which we refer to
as the BCI. We further categorised BCI into three levels: low risk,
BCIo5; intermediate risk, 5pBCIo6.4; high risk, BCIX6.4. These
cut-offs were chosen such that the resulting proportions of low,
intermediate and high risk groups were similar to those formed by
the three categorical combination groups of H:I and MGI. The
endocrine-untreated arm in the Stockholm randomised trial was
used as a testing cohort for BCI.
Clinicopathological risk assessment
The St Gallen’s guidelines were used to assess the risk of
recurrence in the ER-positive tamoxifen-treated and untreated
patients, whereas Adjuvant! Online was used to assess 10-year risk
of recurrence and survival for the ER-positive, node-negative
patients using the following information: tumour grade, tumour
size and age. Multivariate Cox proportional hazard regression
models were used to assess the prognostic performance of
Adjuvant! Online and BCI.
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The primary clinical endpoint used in data analysis was time to
distant metastasis. Distant metastasis-free survival (DMFS) was
defined as the time from diagnosis to first distant metastasis.
Local/regional recurrences before distant metastasis were censored
at the time of relapse. For analysis, data were censored at 15 years,
as 490% of the distant metastatic events occurred before this time
point. Association of gene expression indices with the clinical
endpoint was assessed by the Kaplan–Meier method with the use
of log-rank test and Cox proportional hazard regression. The
proportional hazard assumption was verified by scaled Schoenfeld
residuals. Multivariate Cox proportional hazard regression models
were used to assess whether gene expression indices provided
prognostic information independent of traditional clinical and
histopathological parameters. The hazard ratio for the continuous
BCI score was calculated relative to a 5-unit increment except for
in the multivariate analysis of BCI and Adjuvant! Online. To more
accurately compare BCI with Adjuvant! Online, hazard ratios were
calculated relative to an increment of their inter-quartile ranges
(2.484 for BCI; 8 for Adjuvant! Online). All statistical procedures
are conducted in the statistical software Statistica 9.1 (StatSoft
Scandinavia AB, Uppsala, Sweden) and the free software environ-
ment R (version 2.11.1, http://www.r-project.org/).
RESULTS
Patient and tumour characteristics
The randomised Stockholm trial conducted during 1976 through
1990 examined the efficacy of adjuvant tamoxifen compared with
no adjuvant treatment among postmenopausal women with early-
stage breast cancer. From the ‘low-risk’ patient group (negative
lymph nodes and tumour size p3cm) in this trial, a total of 808
FFPE tumour blocks were retrieved for molecular analysis. After
pathological review, 37 cases had to be excluded because of
insufficient tumour cells or only containing carcinoma in situ.
Reportable gene expression data by real-time RT–PCR were
obtained for all but two samples, leaving a total of 769 cases in the
final analysis (Figure 1). This corresponds to a success rate of
99.7% among the samples assayed. The ER-positive tamoxifen-
treated and untreated patients were examined in this study
(n¼588). Further tumour characteristics of this cohort are
summarised in Table 1.
Association of the combined H:I and MGI with distant
metastasis and breast cancer-specific death
The dichotomous H:I and MGI index was defined for each patient
using pre-specified cut-off values (H:I 0.06 and MGI 0) and a
previously described combination algorithm (low risk, low MGI;
intermediate risk, low H:I and high MGI; and high risk, high H:I
and high MGI) (Ma et al, 2008). Using this approach to estimate
risk among the ER-positive tamoxifen-treated and untreated
patients, the index was significantly associated with both time to
first distant metastasis and breast cancer-specific death within
these independent cohorts. In the tamoxifen-treated patients, more
than 50% of the patients were classified as having a low risk of
recurrence. Kaplan–Meier analysis demonstrated that tamoxifen-
treated patients assigned to the low-risk group had a rate of distant
recurrence or death at 10 years of less than 3% (distant recurrence
rate: 2.9%, 95% CI: 0.4–5.4 (Figure 2A); rate of death: 2.3%, 95%
CI: 0.1–4.5 (data not shown)). The dichotomous H:I and MGI
index also identified 23% of the tamoxifen-treated patients as
intermediate risk and 18% as high risk. In the intermediate and
high-risk groups, the Kaplan–Meier estimates of the rate of distant
recurrence were 16.9% (95% CI: 7.2–25.6) and 16.3% (95% CI:
6.0–25.5; Figure 2A) and estimates of the 10-year rate of breast
cancer-specific death were 13.8% (95% CI: 5.0–21.9) and 11.0%
(95% CI: 2.3–18.9).
A multivariate Cox regression model including tumour grade,
tumour size and the dichotomous H:I and MGI index confirmed
that this risk classification was associated with distant recurrence
independent of tumour size, grade, HER2 status and PR status in
the tamoxifen-treated patients (Table 2). The dichotomous H:I
and MGI index was also prognostic of breast cancer-specific death
independent of tumour size, grade, HER2 status and PR status
(Supplementary Table 1).
The dichotomous H:I and MGI index also demonstrated
prognostic utility in the ER-positive untreated arm of the trial
(P¼0.0004; Figure 2B). Of the untreated cohort, 50% were
classified as low risk, 27% as intermediate risk and 23% as high
risk. The prediction of outcome for the untreated patients showed
a similar pattern but with higher recurrence rates and death rates
than in the tamoxifen-treated patients. In univariate Cox regres-
sion analysis, risk assessment with the dichotomous H:I and MGI
index showed a statistical significance both for distant recurrence,
as well as death due to the disease (data not shown). The rate of
1780 patients with
primary breast cancer
896 cases randomised
to tamoxifen
treatment
884 cases randomised
to no endocrine
treatment
Tissue from 808
samples available for
analysis
37 cases excluded because
of DCIS only or failure
of analysis
398 cases receiving
tamoxifen
371 cases not
receiving endocrine
treatment
314 ER-positive cases 274 ER-positive cases
Figure 1 CONSORT diagram.
Prognostic utility of the Breast Cancer Index
P-L Jerevall et al
1764
British Journal of Cancer (2011) 104(11), 1762–1769 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sbreast cancer-specific death for the low-, intermediate- and high-risk
groups in the untreated arm of the trial was 5.3% (95% CI: 1.4–9.0),
19.3% (95% CI: 9.3–28.3) and 26.3% (95% CI: 14.4–36.7).
In a multivariate analysis, the dichotomous H:IþMGI index
was prognostic of distant recurrence (Table 3) and breast cancer-
specific death (Supplementary Table 2) independent of tumour
size, grade, HER2 status and PR status in the untreated cohort.
Development and testing of H:IþMGI as a continuous
index (BCI)
To enable individual risk assessment of the risk of recurrence, we
developed a continuous algorithm based on the dichotomous H:I
and MGI index. Using the ER-positive tamoxifen-treated patients
in this cohort as a training set, we developed a polynomial function
Table 1 Tumour characteristics for the 588 early-stage postmenopausal
ER-positive breast cancer patients included in this study
Tamoxifen treated Untreated
No. % No. %
Tumour size (mm)
p20 256 82 223 81
420 55 18 49 18
Unknown 3 1 2 1
Tumour grade
16 7 2 1 6 7 2 4
2 209 67 172 63
33 8 1 2 3 5 1 3
PR status
Negative 109 35 107 39
Positive 180 57 139 51
Unknown 25 8 28 10
HER2 status
Negative 272 87 238 87
Positive 14 4 13 5
Unknown 28 9 23 8
Abbreviations: HER2¼human epidermal growth factor receptor 2; PR¼progesterone
receptor.
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Figure 2 Kaplan–Meier estimates of likelihood of distant metastasis, stratified by the combined index of H:I and MGI. (A) ER-positive, tamoxifen-treated
subcohort. (B) ER-positive, untreated subcohort. DMR
z denotes distant metastasis rate.
Table 2 Multivariate Cox regression analysis of distant metastasis for
tamoxifen-treated patients with oestrogen receptor-positive disease
Patients (n)
Hazard ratio
(95% CI) P-value
Multivariate analysis without H:I + MGI
Tumour grade
NHG I 54
NHG II 183 2.6 (0.6–11.4) 0.20
NHG III 36 5.7 (1.2–27.3) 0.03
Tumour size
p20mm 225
420mm 48 1.0 (0.4–2.5) 0.98
HER2
Negative 259
Positive 14 2.1 (0.7–6.4) 0.22
PR
Negative 104
Positive 169 0.8 (0.4–1.7) 0.56
Multivariate analysis with H:I + MGI
Tumour grade
NHG I 54
NHG II 183 1.5 (0.3–7.0) 0.59
NHG III 36 2.0 (0.4–10.7) 0.44
Tumour size
p20mm 225
420mm 48 1.0 (0.4–2.5) 0.96
HER2
Negative 259
Positive 14 1.6 (0.5–5.3) 0.42
PR
Negative 104
Positive 169 0.8 (0.4–1.8) 0.62
H:I + MGI 0.02
Low 155
Intermediate 67 4.2 (1.5–12.1) 0.007
High 51 4.4 (1.4–13.7) 0.01
Abbreviations: HER2¼human epidermal growth factor receptor 2; MGI¼molecular
grade index; NHG¼Nottingham grade; PR¼progesterone receptor.
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sto compute a continuous risk index from H:I and MGI, which we
henceforth refer to as the BCI. Breast Cancer Index provides an
individual risk score on the scale of 0–10 for each patient, which
has a continuous relationship with the rate of distant metastasis at
10 years (Figure 3A). For patient stratification using BCI, we also
defined three risk groups using two cut-off points: BCIo5, low
risk; BCIX5 and o6.4, intermediate risk; BCIX6.4, high risk. BCI
classified 59.6% of the tamoxifen-treated patients as having a low
risk of recurrence (Kaplan–Meier estimates of the rate of distant
recurrence: 1.7%, 95% CI: 0–3.5; rate of death: 1.1%, 95%
CI: 0–2.6 (Figure 3A; data not shown)). Breast Cancer Index also
identified 22.0% of the tamoxifen-treated patients as intermediate
risk and 18.4% as high risk. In the intermediate- and high-risk
groups, the Kaplan–Meier estimates of the rate of distant
recurrence were 17.8% (95% CI: 7.6–26.8) and 20.0% (95%
CI: 8.7–30.0) and estimates of the 10-year rate of breast cancer-
specific death were 14.5% (95% CI: 5.2–22.9) and 14.7% (95%
CI: 4.7–23.6) (data not shown).
To test the performance of the BCI model, the ability of BCI to
predict distant metastasis in the ER-positive patients in the
untreated arm of the Stockholm trial was examined (n¼274). In
these patients, 53, 27 and 20% were classified as low, intermediate
and high risk. The rate of distant metastasis at 10 years in these
risk groups was 8.3% (95% CI: 4.7–14.4), 22.9% (95% CI: 14.5–
35.2) and 28.5% (95% CI: 17.9–43.6), respectively (Figure 3B), and
the rate of breast cancer-specific death was 5.1% (95% CI: 1.3–8.7),
19.8% (95% CI: 10.0–28.6) and 28.8% (95% CI: 15.3–40.2).
Breast Cancer Index was a strong prognostic factor for distant
recurrence independent of tumour size, grade, PR status and HER2
status, although tumour size did contribute prognostic value
(Table 3). Breast Cancer Index was also predictive of breast cancer-
specific death applying a similar multivariate model (Supplemen-
tary Table 2).
Clinicopathological risk assessment
The risk of recurrence was also assessed in both ER-positive
cohorts from the Stockholm trial using the St Gallen’s guidelines.
In the tamoxifen-treated cohort, 22% were classified as low risk
Table 3 Multivariate Cox regression analysis of distant metastasis for
untreated patients with oestrogen receptor positive disease
Patients (n)
Hazard ratio
(95% CI) P-value
Multivariate analysis without H:I + MGI or BCI
Tumour grade
NHG I 53
NHG II 149 1.2 (0.5–2.6) 0.74
NHG III 34 1.6 (0.6–4.4) 0.37
Tumour size
p20mm 190
420mm 46 3.0 (1.6–5.6) 0.0005
HER2
Negative 223
Positive 13 3.0 (1.1–8.3) 0.03
PR
Negative 101
Positive 135 1.3 (0.7–2.4) 0.41
Multivariate analysis with H:I+MGI
Tumour grade
NHG I 53
NHG II 149 0.9 (0.4–2.1) 0.79
NHG III 34 0.9 (0.3–2.8) 0.84
Tumour size
p20mm 190
420mm 46 2.8 (1.5–5.3) 0.001
HER2
Negative 223
Positive 13 2.8 (1.0–7.7) 0.053
PR
Negative 101
Positive 135 1.3 (0.7–2.4) 0.39
H:I+MGI 0.048
Low 116
Intermediate 62 1.8 (0.8–3.9) 0.17
High 58 2.6 (1.2–5.6) 0.01
Multivariate analysis With BCI categories
Tumour grade
NHG I 53
NHG II 149 0.8 (0.3–1.8) 0.55
NHG III 34 0.6 (0.2–1.9) 0.39
Tumour size
p20mm 190
420mm 46 3.0 (1.5–5.6) 0.001
HER2
Negative 223
Positive 13 3.5 (1.2–9.8) 0.019
PR
Negative 101
Positive 135 1.4 (0.7–2.6) 0.30
BCI 0.001
Low 122
Intermediate 66 2.3 (1.1–5.0) 0.03
High 48 4.7 (2.1–10.8) 0.0003
Multivariate analysis with continuous BCI score
Tumour grade 0.89
NHG I 53
NHG II 149 1.3 (0.4–3.8) 0.69
NHG III 34 1.1 (0.3–4.4) 0.91
Table 3 (Continued)
Patients (n)
Hazard ratio
(95% CI) P-value
Tumour size
p20mm 190
420mm 46 2.1 (1.1–4.2) 0.03
HER2
Negative 223
Positive 13 2.1 (0.7–6.4) 0.18
PR
Negative 101
Positive 135 1.0 (0.5–1.9) 0.91
BCI
a 236 7.5 (2.4–23.6) 0.0006
Multivariate analysis with BCI and adjuvant! online
Adjuvant! online
b 246 1.4 (1.0–1.8) 0.03
BCI
b 246 2.0 (1.3–3.1) 0.001
Abbreviations: BCI¼Breast Cancer Index; HER2¼human epidermal growth factor
receptor 2; MGI¼molecular grade index; NHG¼Nottingham grade; PR¼proges-
terone receptor
aAnalysis of BCI as a continuous variable. The hazard ratio for BCI is
calculated relative to a 5-unit increment.
bTo more accurately compare BCI to
Adjuvant! Online, the calculated hazard ratios are relative to an increment of their
inter-quartile ranges, 2.484 for BCI, 6 for Adjuvant! Online.
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sand 78% as intermediate risk with a rate of recurrence of 5.2%
(95% CI:  0.5 to 10.9) and 8.5% (95% CI: 4.9–12.1), respectively.
In the untreated cohort, 19% were classified as low risk and 81% as
intermediate risk with a rate of recurrence of 8.8% (95% CI: 1.4–
16.2) and 17.0% (95% CI: 11.7–22.3) respectively.
The prognostic utility of BCI was also assessed in comparison
with Adjuvant! Online, a web-based tool used to assess risk of
recurrence and breast cancer-specific death based on clinico-
pathological information. In multivariate analyses, both BCI and
Adjuvant! Online were significant predictors of distant recurrence
and death (Table 3 and Supplementary Table 2).
Correlation of BCI with traditional prognostic factors
Comparisons between BCI and classic prognostic factors showed a
correlation with tumour size and tumour grade, as well as HER2
status (Supplementary Table 3). Significantly more patients
categorised into the low-risk group than in the high-risk group
had tumours that were p20mm in size, of a low grade and HER2
negative.
DISCUSSION
It was previously demonstrated that the combination of H:I and
MGI into a dichotomous index outperforms either index alone in
predicting the risk of recurrence in ER-positive, node-negative
breast cancer patients (Ma et al, 2004, 2008). In this study, the
prognostic performance of the dichotomous H:I and MGI index
was validated in a large retrospective analysis of patients from the
randomised Stockholm trial and a continuous risk model of H:I
and MGI (BCI) was developed and tested.
Consistent with previous reports, analysis in this cohort of 588
early stage, postmenopausal ER-positive breast cancer patients
demonstrated that the combination of H:I and MGI was strongly
associated with the risk of distant metastasis and death due to
breast cancer (Ma et al, 2008). The combined H:I and MGI
identified more than 50% of the patients to have a low 10-year
recurrence risk with fewer than 3% of the patients relapsing during
this period of time. Additionally, the results from analysis of the
ER-positive patients not treated with endocrine therapy suggested
that the combined H:I and MGI also has prognostic utility in
untreated patients. H:I and MGI was shown to outperform tumour
grade and PR status in a multivariate analysis, with tumour size
still contributing significant prognostic value only in the untreated
patient population. The results in this study thus confirmed the
previous findings that the combined index performs well
for prediction of breast cancer outcome, both in treated and
untreated patients.
The tamoxifen-treated ER-positive, node-negative cohort from
the Stockholm trial was used to develop the BCI algorithm. The
BCI model was developed to assign a different index score for each
patient, each associated with a different level of individualised risk
of distant recurrence. The BCI scores were categorised into three
levels of recurrence risk (low, intermediate and high) by using
proportional values established with the dichotomous H:I and
MGI index. This entire cohort was used to train the algorithm in
order to retain the entirety of the prognostic information available
with this large, prospective trial and to maximise the accuracy of
BCI to predict a distant metastatic recurrence. An initial test of the
prognostic ability of BCI was carried out in the ER-positive patient
cohort that was not treated with endocrine therapy and not used to
develop BCI. In this untreated cohort, BCI provided similar
prognostic utility compared with that of the combined H:I and
MGI in the untreated cohort. Specifically, BCI classified 53% of the
patients into the low-risk group with a 8.3% risk of distant
recurrence, whereas H:I and MGI stratified 50% of the untreated,
ER-positive patients into the low-risk group with a 9.5% risk of
recurrence. In addition, these results also suggest that the
prognostic utility of BCI extends into untreated patients.
In this study, BCI classified 53, 27 and 20% as low, intermediate
and high risk. In contrast, traditional risk classification based on
clinicopathological criteria, such as suggested by the St Gallen
recommendations from 2005 (Goldhirsch et al, 2006), classifies a
majority of ER-positive, node-negative breast cancer patients as
being of intermediate risk, with few patients in the low- or high-
risk groups. For the low-risk group with endocrine responsiveness,
endocrine therapy remains the primary treatment, but for the
corresponding intermediate group the treatment of choice is not
completely clear, likely resulting in both over and undertreatment.
With BCI, the intermediate risk group was reduced, and a
significantly larger proportion of patients were predicted to have
low risk of recurrence, suggesting additional chemotherapy to be
unnecessary.
The prognostic performance of BCI was also compared with
Adjuvant! Online. In a multivariate analysis, both BCI and
Adjuvant! Online, which estimates risk based on clinicopatholo-
gical information, retained predictive significance suggesting that
they provide complementary information in the assessment of risk
of recurrence and overall survival.
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Figure 3 Breast Cancer Index predicts distant metastasis. A patient is in the low risk group, if BCIo5, intermediate group if 5pBCIo6.4, and high risk
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developed that identify breast cancer patients with a low risk of
recurrence. The 70-gene profile MammaPrint (the Amsterdam
signature; Agendia, BV; Amsterdam, Holland), which is based on a
microarray platform, was developed as a predictor of 5-year risk of
distant metastasis and stratifies patients into low or high risk. It
was reported that MammaPrint classifies B40% of node-negative,
ER-positive and -negative patients into the low-risk group with a
10-year risk of recurrence of 13% in this cohort that was
predominantly untreated (o7% received chemotherapy and
hormonal therapy) (van de Vijver et al, 2002). Oncotype DX
(Genomic Health, Inc., Redwood City, CA, USA) is a quantitative
RT–PCR assay of a panel of 21 genes, which uses a continuous
recurrence score for risk assessment. For decision making in the
clinical setting, three risk groups are defined, with risk assessment
in the ER-positive, node-negative, tamoxifen-treated arm of the
NSABP-B14 trial ranging from 7% in the low-risk to 31% in the
high-risk group (Paik et al, 2004). Risk assessment in the
validation cohort for the dichotomous H:I and MGI index was
consistent with these results, with 59% of the tamoxifen-treated
and 50% of the untreated classified into the low-risk group with a
10-year risk of recurrence of 3 and 10% respectively.
In this study we demonstrate that the combination of H:I and
MGI, either as dichotomous or as a continuous variable (i.e., BCI),
is a significant prognostic for early breast cancer. Studies
determining the prognostic and/or predictive properties of the
individual components of BCI are also ongoing. For example,
within the same cohort, HOXB13 protein expression was demon-
strated to be associated with patient benefit for tamoxifen
treatment (Jerevall et al, 2010). This suggests that in addition to
the strong performance of BCI as a prognostic, its components
may also have predictive properties. Further studies are warranted
to determine whether these findings will extend to current
standard of care of ER-positive patients receiving 5–10 years of
aromatase inhibitors.
CONCLUSIONS
Taken together, this study validates the predictive performance of
the dichotomous H:I and MGI index in a retrospective analysis of
postmenopausal early-stage breast cancer patients randomised to
tamoxifen or no endocrine treatment. We have also developed and
tested a continuous risk index of H:I and MGI, called BCI, for
estimation of recurrence risk at the individual level. The results
from this study suggest that BCI has significant prognostic utility in
an untreated population. Breast Cancer Index has the ability to
identify a large fraction (450%) of patients with a low risk of
distant recurrence at 10 years more accurately than using traditional
risk assessment. These results suggest that BCI may help clinicians
to make better informed treatment decisions and spare toxic
chemotherapy for a large group of breast cancer patients.
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